Compare BGSI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | LIVN |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | N/A | 1993 |
| Metric | BGSI | LIVN |
|---|---|---|
| Price | $164.35 | $62.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $67.38 |
| AVG Volume (30 Days) | 17.4K | ★ 540.7K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $3,101,279,000.00 | $1,348,962,000.00 |
| Revenue This Year | $4.03 | $12.25 |
| Revenue Next Year | $26.52 | $6.68 |
| P/E Ratio | $284.77 | ★ N/A |
| Revenue Growth | 1.42 | ★ 8.63 |
| 52 Week Low | $136.81 | $32.48 |
| 52 Week High | $177.20 | $65.57 |
| Indicator | BGSI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.17 |
| Support Level | N/A | $60.40 |
| Resistance Level | N/A | $65.39 |
| Average True Range (ATR) | 0.00 | 1.55 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 0.00 | 42.28 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.